HK Stock Market Move | Everest MED-B(01952) rebounds more than 5%, drawing attention from international capital. Narcon has a wide future market space.

EVEREST MED-B (01952) rebounded by more than 5%, as of press time, it rose by 5.16% to HK$45.75, with a turnover of HK$89.923 million. On the news front, on January 9th, EVEREST MED-B announced that CBC Group (Concordia Capital, a controlling shareholder of the company) had sold 17.1 million shares to international investors through block trading. After this block trading, CBC Group will continue to hold more than 34% of the issued shares. Industry insiders believe that this transaction is expected to broaden the international investor base within the Everest New Noble Circle, further optimize the company's shareholding structure, and enhance its global market potential. Regarding the stock price fluctuation on January 8th, Everest New Noble stated in the announcement that the Executive Director and CEO Luo Yongqing and Executive Director, President, and CFO He Ying did not sell any shares, and confirmed that there were no significant adverse changes in the business operations or financial condition of the company and its subsidiaries. CEO Luo Yongqing and the management team are optimistic about the company's future development, with a good operating condition, and the management and major shareholders are confident in the company's development. It is worth mentioning that in the field of kidney disease, the globally recognized IgA nephropathy targeted therapy drug Fukuang (Budesonide Enteric Coated Capsules) has been included in the new version of the national medical insurance catalog, with a two-year exclusivity period. With the official implementation of the new national medical insurance catalog, and its commercialization in the Hong Kong region, Everest New Noble will see a surge in sales of this major product. Currently, there are nearly 5 million adult IgA nephropathy patients in China, with young and middle-aged groups as the main patient population, and the market expects its peak sales to reach 5 billion RMB.